Finland's prostate cancer patterns revealed in large data review
NCT ID NCT05701007
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at over 1,000 men with metastatic prostate cancer in the Pirkanmaa region of Finland. Researchers analyzed patient characteristics, treatments used, and outcomes to better understand the disease burden. The goal was to fill gaps in knowledge about how these patients are treated and how the disease progresses in real-world settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION SENSITIVE PROSTATE CANCER (MCSPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Helsinki, Finland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Real-World study eyes drug combo for tough prostate cancer
- New radioactive therapy targets Hard-to-Treat prostate cancer
- New Immune-Boosting drug combo targets Hard-to-Treat cancers
- New prostate cancer drug enters first human trials
- CBD may cut opioid need in advanced prostate cancer
- New cancer drug trial pulled before it even started